| Preface | 6 |
|---|
| Acknowledgments | 7 |
|---|
| Contents | 8 |
|---|
| Contributors | 10 |
|---|
| Shiga-Toxin Producing Escherichia coli and the Hemolytic Uremic Syndrome: What Have We Learned in the Past 25 Years? | 14 |
|---|
| 1 Introduction | 14 |
| 2 History | 15 |
| 3 Epidemiology of E. coli O157:H7 Infections and HUS | 15 |
| 4 Clinical Course of E. coli Infection | 16 |
| 5 Pathophysiology of E. coli O157:H7 Infections | 17 |
| 6 Diagnostic Considerations for Pathogenic STEC | 17 |
| 7 Management of Patients with Confirmed or Suspected E. coli O157:H7 Infection | 19 |
| 8 HUS and the Course of E. coli O157:H7 Infections | 21 |
| 9 Pathophysiology of HUS | 23 |
| 10 Conclusions | 25 |
| References | 26 |
| Global Epidemiology of Pneumococcal Disease-New Prospects for Vaccine Control | 31 |
|---|
| 1 Overview of the Pneumococcus and Pneumococcal Disease | 31 |
| 2 Pneumonia | 32 |
| 3 Invasive Pneumococcal Disease | 32 |
| 4 Acute Otitis Media | 34 |
| 5 Pneumococcal Vaccines | 35 |
| 6 The Power of Pneumococcal Conjugate Vaccines I: Effect of PCV-7 on Rates of IPD in the US after Introduction in 2000 | 36 |
| 7 The Power of Pneumococcal Conjugate Vaccines II: Effect of the 11-Valent PHiD-Conjugate Vaccine on AOM in a Phase III Efficacy Trial | 37 |
| 8 Pneumococcal Vaccines for Adults | 38 |
| 9 Conclusions | 38 |
| References | 39 |
| Current Concepts of the Pathogenesis of RSV Bronchiolitis | 42 |
|---|
| 1 Introduction | 42 |
| 2 Genetic Determinants of RSV Bronchiolitis and Post-bronchiolitis Wheeze | 43 |
| 3 Pre-existent Airway Morbidity | 45 |
| 4 Immature Immune Responses | 45 |
| 5 Immunopathogenesis | 46 |
| 6 Parallel Versus Serial Hypothesis | 47 |
| 7 Conclusions | 48 |
| References | 48 |
| How Can We Eradicate Pertussis | 52 |
|---|
| 1 Introduction | 52 |
| 2 Bordetella pertussis: The Organism and Its Pathogenesis | 52 |
| 3 Clinical Disease | 53 |
| 3.1 Pertussis in Young Infants | 54 |
| 3.2 Adults | 54 |
| 4 Laboratory Diagnosis of B. pertussis Infection | 55 |
| 4.1 Culture | 55 |
| 4.2 Direct Detection of B. pertussis | 55 |
| 4.3 Serologic Diagnosis of B. pertussis Infection | 55 |
| 5 Epidemiology | 56 |
| 5.1 Reported Pertussis | 56 |
| 5.2 Epidemiology of B. pertussis Infections | 57 |
| 6 Vaccines | 59 |
| 7 Conclusions | 61 |
| References | 61 |
| Recognition and Management of Encephalitis in Children | 63 |
|---|
| 1 Introduction | 63 |
| 2 History | 63 |
| 3 Etiology | 64 |
| 4 Postimmunization Neurological Disease | 66 |
| 5 Postinfectious Encephalitis | 66 |
| 6 Chronic Encephalitic or Encephalopathic Illnesses (Slow Infections) | 67 |
| 7 Encephalitis Epidemiology | 67 |
| 8 Clinical Manifestations | 67 |
| 9 Differential Diagnosis | 68 |
| 10 Specific Diagnosis | 68 |
| 11 Treatment | 69 |
| 12 Prognosis | 70 |
| 13 Prevention | 70 |
| References | 70 |
| Microbiology and Management of Pleural Empyema | 71 |
|---|
| 1 Introduction | 71 |
| 2 Epidemiology and Aetiology | 72 |
| 2.1 Epidemiology | 72 |
| 2.2 Aetiology | 72 |
| 2.3 Risk Factors for Progression to Empyema | 73 |
| 3 Potential Reasons for Increasing Incidence of Empyema | 74 |
| 3.1 Serotype 1 | 74 |
| 3.2 Sequence Types | 74 |
| 4 Management | 75 |
| 4.1 Prevention | 75 |
| 4.2 Drainage of Fluid | 75 |
| 5 Summary | 76 |
| References | 77 |
| Pneumococcal Conjugate Vaccines Probe Studies: The Solution Points to the Problem | 79 |
|---|
| 1 Observed Versus Expected Effect of a Vaccine - The Vaccine Probe Concept | 79 |
| 2 Vaccine Probe-Derived Insights into PCVs - Selected Examples | 80 |
| 2.1 Probe Studies in Pneumonia - the pneumonia detective | 80 |
| 3 Potential Role of PCVs in the Prevention of Mortality in Developing Populations | 82 |
| 4 Indirect Effect of PCV - the Herd Immunity Effect | 82 |
| 5 How Many Doses of PCV Are Appropriate for Infant Immunization Programs? | 83 |
| 6 Hypothesis Generating Results: A Study on Social Mixing During Infancy and Antibody Response to PCV7 at 1 Year of Age | 85 |
| 7 Conclusions | 85 |
| References | 86 |
| New Findings in Primary Immunodeficiency | 88 |
|---|
| 1 Introduction | 88 |
| 2 Severe Combined Immunodeficiency | 88 |
| 2.1 New T Lymphocyte Receptor Signalling Defects | 90 |
| 2.1.1 CD3 zeta Subunit Deficiency | 90 |
| 2.1.2 ORAI Deficiency | 90 |
| 2.2 New Defects of T and B Lymphocyte Receptor Recombination | 90 |
| 2.2.1 DNA Ligase IV Deficiency | 90 |
| 2.2.2 Cernunnos-XLF Deficiency | 91 |
| 3 X-Linked Lymphoproliferative Syndromes | 91 |
| 4 Common Variable Immunodeficiency | 92 |
| 4.1 Inducible Costimulator Deficiency | 92 |
| 4.2 CD19 Deficiency | 92 |
| 4.3 Transmembrane Activator and Calcium-Modulating Cyclophilin Lig
|